Transplant Biomedicals, CataloniaBio & HealthTech member, has completed patient enrolment of the clinical trial of Vivian® device for the transport and preservation of kidneys for transplantation. 

It is a multicenter and prospective study designed to evaluate the safety and performance of Vivian® in 32 patients of Hospital Clínic Barcelona, Vall d’Hebron University Hospital and Bellvitge University Hospital. Interim results are expected to be available next May and complete results in 1Q 2020.

“Vivian® has the profile of a true game changer in organ preservation market, and our development plan is poised to explore all these opportunities” says Dr. Joan Salgado, CEO of Transplant Biomedicals.

Transplant Biomedicals pursues a total target market of €1.1 billion and now is seeking €13.6 million in order to complete the clinical development, final product and market launch of Vivian® , and further pursue early pipeline.

Photo: New Vivian® device designed in Barcelona - © Transplant Biomedicals